Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCP for COVID-19 prevention in HSCT
NCT05904067Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2023
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Prevalence of new COVID infection at 1 year. Status: unknown.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05904067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904067.